Skip to main content
Astria Therapeutics, Inc. logo

Astria Therapeutics, Inc. — Investor Relations & Filings

Ticker · ATXS ISIN · US04635X1028 US Manufacturing
Open in API
Filings indexed 602 across all filing types
Latest filing 2025-10-17 Major Shareholding Noti…
Country US United States of America
Listing US ATXS

About Astria Therapeutics, Inc.

https://astriatx.com/

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for allergic and immunologic diseases. The company's mission is to provide life-changing treatments to patients and their families. Its lead product candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein being developed as a potential long-acting, preventative treatment for Hereditary Angioedema (HAE). The company has reported positive initial proof-of-concept results from its ALPHA-STAR Phase 1b/2 clinical trial for STAR-0215. Astria Therapeutics is guided by patient needs to develop differentiated therapeutics that address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-17 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-15 English
FORM 8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content describes an Agreement and Plan of Merger between Astria Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc., detailing the terms of the merger, merger consideration, stock options, warrants, closing conditions, termination rights, and other related information. The document is not a full annual or quarterly report, nor is it an earnings release or audit report. It is a regulatory filing announcing a significant corporate transaction, specifically a merger agreement. The presence of detailed merger terms and conditions aligns with filings related to M&A activity. The document is not a proxy solicitation or voting results announcement, but rather a current report disclosing the merger agreement. Therefore, the most appropriate classification is M&A Activity (Code: TAR). The document length and detail support a high confidence in this classification.
2025-10-14 English
425 Filing
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 14, 2025, by Astria Therapeutics, Inc. It announces the entry into a material definitive agreement, specifically an Agreement and Plan of Merger between Astria Therapeutics and BioCryst Pharmaceuticals. The text details the terms of the merger, including merger consideration, stock options, warrants, closing conditions, termination rights, and other related information. This type of filing is a current report disclosing a significant corporate event, namely a merger agreement. It is not a full annual or quarterly report, nor is it an earnings release or proxy statement. It is also not a regulatory certification or a voting result announcement. The document fits the category of M&A Activity announcements, which cover merger proposals and takeover bids. Therefore, the appropriate classification is TAR (M&A Activity). The document length (15,000 characters) and detailed content support a high confidence in this classification.
2025-10-14 English
425 Filing
Merger & Acquisition Classification · 100% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934, indicating it is related to merger communications. It contains multiple communications including a LinkedIn post, emails to employees, partners, and physicians, all discussing the proposed merger between Astria Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. The document references the expected closing of the transaction, regulatory approvals, and stockholder approvals. It also mentions the forthcoming filing of a registration statement on Form S-4, which will include a proxy statement/prospectus related to the merger. The content is focused on the merger announcement and related communications rather than financial results or detailed financial data. Therefore, this document fits the category of Merger & Acquisition filings, specifically Form 425 communications related to merger proposals.
2025-10-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.